Blueprint Medicines

$92.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.60 (+0.65%) As of 5:18 PM UTC today

Why Robinhood?

You can buy or sell BPMC and other stocks, options, and ETFs commission-free!

About BPMC

Blueprint Medicines Corporation Common Stock, also called Blueprint Medicines, is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA. The listed name for BPMC is Blueprint Medicines Corporation Common Stock.

CEO
Jeffrey W. Albers
Employees
429
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
5.81B
Price-Earnings Ratio
16.65
Dividend Yield
—
Average Volume
505.13K
High Today
$93.51
Low Today
$89.05
Open Price
$93.51
Volume
382.54K
52 Week High
$125.61
52 Week Low
$43.29

BPMC Earnings

-$2.28
$2.20
$6.68
$11.16
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 5, Pre-Market

You May Also Like

DFEN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure